Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
39 hedge funds and large institutions have $26.4M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 22 increasing their positions, 7 reducing their positions, and 6 closing their positions.
214% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 7
55% more capital invested
Capital invested by funds: $17.1M → $26.4M (+$9.32M)
9% less funds holding
Funds holding: 43 → 39 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$274K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$226K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$72.3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$67.7K |
| 5 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
+$46.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$375K |
| 2 |
Renaissance Technologies
New York
|
-$115K |
| 3 |
Squarepoint
New York
|
-$106K |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$35K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$31K |
ELOX Hedge Fund Activity: Q2 2020 in Review
39 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q2 2020, worth a combined $26.4M — up 55% from $17.1M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ELOX and 2 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 22 added.
The largest buyer was BlackRock, adding an estimated $274K. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $375K sold.
- 39 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q2 2020, down from 43 in Q1 2020.
- Funds reported $26.4M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q2 2020, up 55% quarter-over-quarter.
- 2 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q2 2020 and 6 closed out, a net change of -4 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $274K added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q2 2020 was DAFNA Capital Management, an estimated $375K sold.
Based on aggregated 13F filings for Q2 2020.